Efficiency Of Hormone Stimulation Treatment Before Hypospadias Surgery: Experimental Study
DOI:
https://doi.org/10.52783/jns.v14.2992Keywords:
Hypospadias, preoperative hormone stimulation, rat preputium, experimental study, surgical timingAbstract
Aim: In severe forms of hypospadias the penis may be small and the surrounding tissues may be weak. There is a relationship between size of the penis and surrounding tissues and the success of the hypospadias surgery. As the penis size gets smaller and the surrounding tissues are inadequate; the chance of surgical success decreases. Hormone treatments are used to increase penile size and tissue development. However, there is no consensus on the choice of hormone preparation to be used, how long the treatment should be done, and the timing of the surgical treatment to be performed. The purpose of this study, is to observe structural and histopathologic changes of hormone stimulation therapy methods in the healthy (without hypospadias) animal model and as a result of these observations, decide on the ideal surgical time period after hormone stimulation.
Material and method: 50 Wistar Albino rats, which were 4-6 weeks old, were used. Rats were divided into 5 groups as parenteral human chorionic gonadotropin group, parenteral testosterone group, topical dihydrotestosterone group, parenteral control group and topical treatment control group. Penis diameter and length were measured weekly at the beginning of the application, throughout the study and after the application. Biopsies were taken from preputium for histopathologic examination at 0, 1, 3, 6, 7 and 8th weeks. Biopsies were evaluated for vascularity, epithelial thickness, inflammation and fibrosis.
Results: In the group of which parenteral human chorionic gonadotropin was given; an increase of 56% in penile length, 58% in penile diameter and 84% in number of vessels in preputium biopsies was achieved. Increases in penile length, diameter and number of vessels were statistically significant when compared to the control group.
In the parenteral testosterone-administered group, an increase of 62% in the length of the penis, 59,8% in the diameter of the penis and 109% in the number of vessels in the preputium biopsies was observed. Increases in penile length, diameter and number of vessels were statistically significant when compared to the control group.
In the topical testosterone-administered group, an increase of 46% in the length of the penis, 59% in the diameter of the penis and 100% in the number of vessels in the preputium biopsies was observed. Increases in penile length and number of vessels were statistically significant when compared to the control group.
Conclusion: This study has shown that human chorionic gonadotropin, parenteral testosterone and topical dihydrotestosterone treatments are useful in increasing penile size and tissue quality before hypospadias surgery. It was observed that parenteral testosterone was the most effective among these hormone stimulation treatment regimens. In addition, this study showed that hormone stimulation treatments did not exacerbate inflammation and fibrosis, but periodically suppressed. The best time for surgical repair starting from the end of drug administration was found as after the 4th week in parenteral human chorionic gonadotropin group, after the 6th week in parenteral testosteron group and after the 1st week in testosteron group.
Downloads
Metrics
References
Koff SA, Jayanthi VR. Preoperative treatment with human chorionicgonadotropin in infancy decreases the severity of proximal hypospadias and chordee. J Urol. 1999; 162:1435-9.
Snodgrass WT, Villanueva C, Granberg C, Bush NC. Objective use of testosterone reveals androgen insensitivity in patients with proximal hypospadias. J Pediatr Urol. 2014; 10:118-22.
Luo CC, Lin JN, Chiu CH, Lo FS. Use of parenteral testosterone prior to hypospadias surgery. Pediatr Surg Int. 2003; 19:82-4.
de Mattos e Silva E, Gorduza DB, Catti M, Valmalle AF, Demède D, Hameury F, Pierre-Yves M, Mouriquand P. Outcome of severe hypospadias repair using three different techniques. J Pediatr Urol. 2009 Jun;5(3):205-11; discussion 212-4. doi: 10.1016/j.jpurol.2008.12.010. Epub 2009 Feb 7.
Stern JM1, Chen J, Peters SB, Stahl PJ, El-Chaar M, Felsen D, Poppas DP. Testosterone treatment of human foreskin in a novel transplant model. Urology. 2004; 63:999-1003.
Bastos AN, Oliveira LR, Ferrarez CE, de Figueiredo AA, Favorito LA, Bastos Netto JM. Structural study of prepuce in hypospadias--does topical treatment with testosterone produce alterations in prepuce vascularization? J Urol. 2011; 185:2474-8.
Asgari SA, Safarinejad MR, Poorreza F, Asl AS, Ghanaie MM, Shahab E.The effect of parenteral testosterone administration prior to hypospadias surgery: A prospective, randomized and controlled study. J Pediatr Urol. 2015; 11:143.
Sordello S, Bertrand N, Plouët J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun. 1998; 251:287-90.
Kaya C, Radmayr C. The role of pre-operative androgen stimulation in hypospadias surgery. Transl Androl Urol. 2014; 3:340-6.
Malik RD, Liu DB. Survey of pediatric urologists on the preoperative use of testosterone in the surgical correction of hypospadias. J Pediatr Urol. 2014; 10:840-3.
Netto JM, Ferrarez CE, Schindler Leal AA, Tucci S Jr, Gomes CA, Barroso U Jr. Hormone therapy in hypospadias surgery: a systematic review. J Pediatr Urol. 2013; 9:971-9.
Zhao W, Yin J, Yang Z, Xie J, Zhang Y, Xu W, Li JL. Meta-analysis of Androgen Insensitivity in Preoperative Hormone Therapy in Hypospadias. Urology. 2015; 85:1166-72.
Gorduza DB, Gay CL, de Mattos E Silva E, Demède D, Hameury F, Berthiller J, Mure PY, Mouriquand PD. Does androgen stimulation prior to hypospadias surgery increase the rate of healing complications? - A preliminary report. J Pediatr Urol. 2011; 7:158-61.
Shima H, Ikoma F, Yabumoto H, Mori M, Satoh Y, Terakawa T, Fukuchi M. Gonadotropin and testosterone response in prepubertal boys with hypospadias. J Urol 1986; 135:539-42.
Klugo RC, Cerny JC. Response of Micropenis to Topical Testosterone and Gonadotropin. J Urol 1978; 119:667-668.
Diaz Gomez LA, Lagaron Comba E, Perez Escariz P. Response of micro penis to topical testosterone and gonadotrophines: a comparative study. An Esp Pediatr 1982; 16:145-52.
Ahmad R, Chana RS, Ali SM, Khan S. Role of parenteral testosterone in hypospadias: a study from a teaching hospital in India. Urol Ann 2011; 3:138-40.
Nerli RB, Koura A, Prabha V, Reddy M. Comparison of topical versus parenteral testosterone in children with microphallic hypospadias. Pediatr Surg Int. 2009; 25:57-9.
Gearhart JP, Jeffs RD. The use of parenteral testosterone therapy in genital reconstructive surgery. J Urol. 1987; 138:1077-8.
Chalapathi G1, Rao KL, Chowdhary SK, Narasimhan KL, Samujh R, Mahajan JK. Testosterone therapy in microphallic hypospadias: topical or parenteral? J Pediatr Surg. 2003; 38:221-3.
Ishii T, Hayashi M, Suwanai A. The effect of intramuscular testosterone enanthate treatment on stretched penile length in prepubertal boys with hypospadias. Urology. 2010; 76:97-100.
Davits RJ, van den Aker ES, Scholtmeijer RJ, de Muinck Keizer-Schrama SM, Nijman RJ. Effect of parenteral testosterone therapy on penile development in boys with hypospadias. Br J Urol. 1993; 71:593-5.
Dodge-Khatami A, Backer CL, Holinger LD. Healing of a free tracheal autograft is enhanced by topical vascular endothelial growth factor in an experimental rabbit model. J Thorac Cardio- vasc Surg 2001; 122:554-61.
Kaya C, Bektic J, Radmayr C, Schwentner C, Bartsch G, Oswald J. The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study. J Urol. 2008; 179:684-8.
Hassan JM, Pope JC, Revelo P, Adams MC, Brock JW, DeMarco RT. The role of postoperative testosterone in repair of iatrogenic hypospadias in rabbits. J Pediatr Urol. 2006; 2(4):329-32.
Gilliver SC, Wu F, Ashcroft GS. Regulatory roles of androgens in cutaneous wound healing. Thromb Haemost, 2003; 90:978-85.
Gilliver SC, Ruckshanthi JPD, Hardman MJ. 5-Dihydrotestosterone (DHT) retards wound closure by inhibiting re-epithelialization. J Pathol 2009; 217:73-82.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
